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Pollack et al S78.e2Background: Population-based data on melanoma survival are important for understanding the impact of
demographic and clinical factors on prognosis.Objective: We describe melanoma survival by age, sex, race/ethnicity, stage, depth, histology, and site.Methods: Using Surveillance, Epidemiology, and End Results data, we calculated unadjusted cause-specific
survival up to 10 years fromdiagnosis for 68,495 first primary cases ofmelanomadiagnosed from1992 to 2005.
Cox multivariate analysis was performed for 5-year survival. Data from 1992 to 2001 were divided into 3 time
periods to compare stage distribution and differences in stage-specific 5-year survival over time.Results: Melanomas that had metastasized (distant stage) or were thicker than 4.00 mm had a poor
prognosis (5-year survival: 15.7% and 56.6%). The 5-year survival for men was 86.8% and for persons given
the diagnosis at age 65 years or older was 83.2%, varying by stage at diagnosis. Scalp/neck melanoma had
lower 5-year survival (82.6%) than other anatomic sites; unspecified/overlapping lesions had the least
favorable prognosis (41.5%). Nodular and acral lentiginous melanomas had the poorest 5-year survival
among histologic subtypes (69.4% and 81.2%, respectively). Survival differences by race/ethnicity were
observed in the unadjusted survival, but nonsignificant in the multivariate analysis. Overall 5-year
melanoma survival increased from 87.7% to 90.1% for melanomas diagnosed in 1992 through 1995
compared with 1999 through 2001, and this change was not clearly associated with a shift toward localized
diagnosis.Limitations: Prognostic factors included in revised melanoma staging guidelines were not available for all
study years and were not examined.Conclusions: Poorer survival from melanoma was observed among those given the diagnosis at late stage
and older age. Improvements in survival over time have been minimal. Although newly available therapies
may impact survival, prevention and early detection are relevant to melanoma-specific survival. ( J Am
Acad Dermatol 2011;65:S78.e1-10.)
Key words: anatomic sites; cancer registry; histology; melanoma; survival.More than 50,000 people are given the diagnosis
of melanoma in the United States every year,
according to the US Cancer Statistics report.1 In
addition to the stage at diagnosis, previous studies
have shown other factors are related to prognosis
such as histology, location on body, and socioeco-
nomic status (SES).2-5 In this study, we used the data
from population-based cancer registries to describe
melanoma survival by demographic and clinical
factors.
METHODS
We analyzed data from the 13 registries that
participate in the National Cancer Institutethe Division of Cancer Prevention and Control, Centers for
isease Control and Prevention, Atlantaa; Louisiana Tumor
gistry, Epidemiology Program, School of Public Health,
uisiana State University Health Sciences Centerb; Depart-
ents of Dermatology and Pathology/Laboratory Medicine,
ory University School of Medicine, Atlantac; and Atlanta
epartment of Veterans Affairs Medical Center, Decatur.d
ication of this supplement to the JAAD was supported by the
ivision of Cancer Prevention and Control, Centers for Disease
ontrol and Prevention (CDC).Surveillance, Epidemiology, and End Results (SEER)
program (Atlanta, GA; Connecticut; Detroit, MI;
Hawaii; Iowa; New Mexico; San Francisco-Oakland,
CA; Seattle-Puget Sound, WA; Utah; Los Angeles, CA;
San Jose-Monterey, CA; rural Georgia; and the Alaska
Native Tumor Registry). The coverage of these SEER-
13 registries represented 14% of the US population
and met uniform data standards for cancer
registration.6
We identified 133,386 cases of melanoma diag-
nosed between 1992 and 2005 at age 15 years or
older and reported to a SEER-13 registry. We ex-
cluded 37,160 in situ melanoma cases (27.9%);
26,282 melanoma cases that were not the first cancerConflicts of interest: None declared.
The opinions or views expressed in this supplement are those of
the authors and do not necessarily reflect the opinions,
recommendations, or official position of the journal editors or
the Centers for Disease Control and Prevention.
Accepted for publication May 13, 2011.
Reprint requests: Jun Li, MD, PhD, MPH, Centers for Disease
Control and Prevention, 4770 Buford Hwy NE, Mailstop K-55,
Atlanta, GA 30341. E-mail: ffa2@cdc.gov.
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S78.e3 Pollack et aldiagnosed (19.7%); 145 cases found by death certif-
icate only or autopsy; 275 cases not microscopically
confirmed; 318 cases with an unknown cause of
death; 88 patients with unknown age; and 623
patients who had no survival time. Our final study
population included 68,495 first primary invasive
melanoma cases diagnosed in years 1992 to 2005CAPSULE SUMMARY
d Cancer registry data were used to
calculate cause-specific survival up to 10
years from diagnosis for 68,495 first
primary cases of melanoma diagnosed
from 1992 to 2005.
d Poorer survival from melanoma was
observed among those given the
diagnosis at late stage and older age.
d Improvements in survival over time have
been minimal.and followed up through
2006 to ensure at least 12
months of complete follow-
up. Melanoma cases were
identified by International
Classification of Diseases
for Oncology, Third Edition
morphology codes (C440-
C449)7 and categorized by
histologic subtype as super-
ficial spreading, lentigo
maligna, acral lentiginous,
nodular, not otherwise spec-
ified, and other.8 We chose
not to collapse the histologic
category ‘‘not otherwise
specified’’ with ‘‘other’’ because the survival pat-
terns for these two subtypes were different. A
revised staging system for melanoma was intro-
duced in the sixth edition of the American Joint
Committee on Cancer (AJCC) Cancer Staging
Manual and implemented into cancer registries in
2003.9 To ensure consistency in staging across all
study years, we used SEER historic stage, which
provides consistent definitions over time (as op-
posed to AJCC staging, which is more commonly
used in the clinical settings).10 SEER historic stages
were localized (confined to primary site), regional
(spread to regional lymph nodes), distant (cancer
hadmetastasized), and unknown (unstaged). Depth
of melanoma was classified as less than or equal to
1 mm, 1.01 to 2.00 mm, 2.01 to 4.00 mm, and greater
than 4.00mm.Anatomic siteswere classified as face/
ears (C440-C443), scalp and neck (C444), trunk
(C445), extremities (C446-447), and not otherwise
specified/overlapping codes (C448-C449).7 Scalp
and neck melanomas have been shown to have
poorer survival than melanomas on the face, ear,
and other anatomic sites,3 thus we analyzed them
separately. Information on race and ethnicity was
obtained from medical records by tumor registrars
who reported melanoma to the SEER program.6
Identification of cases having Hispanic ethnicity was
enhanced with the North American Association of
Central Cancer Registries Hispanic Identification
Algorithm.11 The availability and quality of variables
on receipt of surgery, sentinel lymph node biopsy
(SLNB), and radiation were limited, especially in theearlier years, and therefore not included in this
analysis.
Analysis
Our main outcome of interest was survival time
after a diagnosis of melanoma as the primary
cancer. The cause of death information was fromdeath certificates. We present
cause-specific survival (eg,
melanoma-specific survival
[MSS]). For the unadjusted
analyses, we used the
Kaplan-Meier method to cal-
culate MSS by gender, age at
diagnosis, race, Hispanic eth-
nicity, stage and depth at
diagnosis, anatomic site,
and histologic subtype. To
examine temporal trends in
survival, we stratified cases
into 3 time periods (1992-
1995, 1996-1998, and 1999-
2001). For this analysis ofsurvival time by time period and stage, we excluded
cases diagnosed after 2001 to have a full 5 years of
follow-up. We used the Z-test to examine any differ-
ences in 5-year survival between the earliest and
most recent time period and x2 to test for any
significant change in the proportion of cases diag-
nosed at the local, regional, distant, and unknown
stage (eg, stage distribution).
We explored whether survival differences can be
explained by sociodemographic and clinical charac-
teristics by performing a multivariate analysis for
MSS using Cox regression modeling. Because of
missing information on race/ethnicity, stage at diag-
nosis, and depth, this multivariate analysis was
based on 56,886 study cases. We restricted the
follow-up time in the Cox model to a 5-year
follow-up period. We assessed the Cox proportional
hazards assumption for each covariate by graphical
examination of the log of the negative log survival
curves versus time and by the Schoenfeld residual
correlation test. Variables for histologic subtype and
anatomic site were both found to violate the Cox
proportional hazards assumption. Thus, the final
Cox model was stratified on histologic subtype and
anatomic site and included sex, age at diagnosis,
race/ethnicity, stage at diagnosis, and depth.12,13
Hazard ratios (HR) and corresponding 95% confi-
dence intervals (CI) were estimated to determine
statistical significance. All the analyses were per-
formed using SEER*Stat, Version 6.6 (IMS Inc, Silver
Springs, MD) and SAS, Version 9.2 (SAS Institute,
Cary, NC).
Abbreviations used:




SEER: Surveillance, Epidemiology, and End
Results
SES: socioeconomic status
SLNB: sentinel lymph node biopsy
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This study included 68,495 invasive melanoma
cases diagnosed from 1992 to 2005 in the 13 SEER
registries. Table I shows the distribution of mela-
noma incidence by demographic and clinical char-
acteristics and 1-, 5-, and 10-year MSS. Figs 1 and 2
show Kaplan-Meier cause-specific survival curves.
Overall, the 1-year MSS was 96.9%. The 5- and 10-
year MSS were 89.2% and 85.1%. The MSS for males
and females was 96.3% and 97.7% at year 1 and
86.8% and 92.0% at year 5, respectively. Age at
diagnosis impacted survival. Men and women given
the diagnosis at age 65 years and older had a lower
5-year survival than those at age 40 to 64 years and
15-39 years (83.2% vs 90.6% and 94.4%) (Table I). As
time from diagnosis increased, so did the differences
between the MSS of the oldest and younger age
groups (Fig 1). The 10-year MSS was 77.0% for cases
diagnosed at age 65 years, which was lower than
86.7% and 91.9% for the two younger age cate-
gories. We analyzed MSS by age and stage at
diagnosis and found that the difference between
the youngest (15-39 years) and oldest ($ 65 years)
age group was more pronounced for regional stage
melanomas (73.5% vs 58.2%) than localized stage
(98.0% vs 92.3%) (data not shown). Whites ac-
counted for 95.2% of the study population and
had a favorable prognosis at diagnosis (96.9% 1-
year and 89.0% 5-year MSS) compared with blacks
(72.2% 5-year MSS) and Asian/Pacific Islanders
(79.2% 5-year MSS). Ethnicity also impacted sur-
vival. Non-Hispanic whites had a higher 5-year
survival than Hispanic whites (89.2% vs 82.9%).
Melanoma diagnosed at the localized stage had a
99.7% 1-year MSS, but despite early detection there
were still deaths attributable to melanoma at the
localized stage (10-year MSS 92.1%). In contrast,
diagnoses at a distant stage had poor prognoses
(1-year MSS 41.3%). For regional and distant stage
melanomas, MSS decreased rapidly from year 1 to
year 3 and then stabilized from year 5 to year 10 (Fig
2, A). Given that depth of melanoma is a major
determinant of stage of diagnosis, as expected,
lesions less than 1.00 mm had a 5-year MSS of97.4% whereas the 5-year MSS for lesions that were
2.01 to 4.00 mm was 72.7% and, for lesions with a
depth greater than 4.00 mm, MSS was 56.6% (Fig 2,
B). Two histologic subtypes with favorable progno-
sis were superficial spreading and lentigo maligna.
For both, MSS exceeded 99% at year 1, 95% MSS at
year 5, and remain over 92% at year 10 (Fig 2, C ). In
contrast, the 1-, 5-, and 10-year MSS of nodular and
acral lentiginous melanoma were substantially dif-
ferent. Survival by anatomic site was similar for
melanoma diagnosed on the face/ears, trunk, and
extremities (5-year MSS 90.2%, 91.2%, 92.5%) but
less for melanoma on the scalp and neck (5-year
MSS 82.6%, 10-year MSS 75.6%) and unspecified and
overlapping lesions (5-year MSS 41.5%) (Fig 2, D).
A modest increase in the overall 5-year cause-
specific survival for melanoma was observed
between the time periods of 1992 to 1995 (87.7%
[95% CI 87.1-88.2]) and 1999 to 2001 (90.1% [95% CI
89.6-90.5]) (Table II). Comparing these two time
periods, there was a decrease in the proportion of
unstaged cases from 5.9% to 2.1% of overall cases
(P \ .001). Among the cases that were staged,
compared with cases diagnosed in 1992 through
1995, the proportion of localized cases decreased in
the most recent time period of 1999 to 2001, whereas
the proportion of cases diagnosed at the regional
stage increased, and the change in proportion diag-
nosed at the distant stage was very small (P\.001 for
overall change in distribution). Patients given the
diagnosis at the localized and regional stages from
1999 to 2001 had significantly increased 5-year sur-
vival compared with patients given the diagnosis of
same-stage cancer from 1992 to 1995. For melanoma
diagnosed at a distant stage, there was a slight, but
not significant, increase in 5-year MSS from the
earliest to latest diagnostic time period.
After controlling for demographic and clinical
factors through multivariate analysis, we found sex
and age remained significantly associated with
5-year survival (Table III). The risk of death for
females was lower than for males (HR 0.76
[0.71-0.81]), as were the two younger age groupings
(HR 0.66 [0.62-0.71] for ages 40-64 years and HR 0.49
[0.44-0.54] for ages 15-39 years) comparedwith those
older than 65 years. Racial/ethnic differences in
survival were attenuated in our multivariate model.
The risk of melanoma death for blacks was over one-
third higher than for non-Hispanic whites, but did
not reach statistical significance (HR 1.33 [0.98-1.78]).
The survival differences by Hispanic ethnicity (lim-
ited to cases of white race) also lost significance in
the multivariate analysis (HR 1.06 [0.92-1.24]). We
found the stage at diagnosis and depth of melanoma
to be important factors related to 5-year survival.
Table I. Demographic and clinical characteristics of patients with invasive melanoma, Surveillance,
Epidemiology, and End Results-13, 1992 to 2005
Melanoma-specific survival, %
Characteristic No. Percentage 1-y 5-y 10-y
Overall 68,495 96.9 89.2 85.1
Sociodemographic
Sex
Male 37,626 54.9 96.3 86.8 82.0
Female 30,869 45.1 97.7 92.0 88.8
Age at diagnosis, y
15-39 13,383 19.5 98.6 94.4 91.9
40-64 33,526 48.9 97.4 90.6 86.7
$ 65 21,586 31.5 95.1 83.2 77.0
Race/ethnicity*
White 65,174 95.2 96.9 89.0 84.8
White, non-Hispanic 63,140 92.2 96.9 89.2 85.0
White, Hispanic 2034 3.0 95.1 82.9 79.0
Black 318 0.5 89.5 72.2 68.2
Asian/Pacific Islander 593 0.9 94.4 79.2 71.7
American Indian/Alaskan Native 124 0.2 93.5 79.5 74.6
Other/unknown 2286 3.3 99.8 99.2 98.0
Hispanic 2104 3.1 95.3 83.3 79.5
Clinical
Stage at diagnosis
Localized 56,504 82.5 99.7 95.6 92.1
Regional 7365 10.8 93.6 63.7 54.3
Distant 2253 3.3 41.3 15.7 12.8
Unstaged 2373 3.5 93.4 80.3 74.2
Depth, mm
No mass/tumor found 483 0.7 57.4 34.5 26.4
0.01-1.00 40,935 59.8 99.6 97.4 95.2
1.01-2.00 9520 13.9 98.7 88.4 81.2
2.01-4.00 5190 7.6 96.5 72.7 62.1
[4.00 2955 4.3 91.1 56.6 46.6
Unknown 9412 13.7 87.4 75.4 71.2
Histologic subtype
Superficial spreading 26,054 38.0 99.5 95.8 92.6
Lentigo maligna 4297 6.3 99.7 96.3 92.4
Acral lentiginous 785 1.1 97.7 81.2 67.9
Nodular 4998 7.3 94.3 69.4 60.8
NOS 29,445 43.0 94.7 86.2 82.2
Others 2916 4.3 96.2 83.4 78.1
Anatomic site
Face/ears 8153 11.9 98.4 90.2 85.5
Scalp/neck 4328 6.3 96.6 82.6 75.6
Trunk 23,293 34.0 98.3 91.2 87.1
Extremities 29,990 43.8 98.7 92.5 88.8
Upper limb/shoulder 16,229 23.7 98.7 93.0 89.5
Lower limb/hip 13,761 20.1 98.6 91.8 88.0
NOS/overlapping 2731 4.0 61.7 41.5 38.2
NOS, not otherwise specified.
*Hispanics were not mutually exclusive from race. Whites included both non-Hispanic whites and Hispanic whites.
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Our study results are consistent with earlier re-
ports that stage at diagnosis and depth are significant
factors related to MSS.9 Although depth is one factorthat determines stage, the correlation between them
was modest (21%), therefore, we kept both depth
and stage in the model. Sex and age also remained
significant prognostic factors in the adjusted analysis,
Fig 1. Unadjusted Kaplan-Meier melanoma-specific sur-
vival curve by age at diagnosis, Surveillance, Epidemiol-
ogy, and End Results-13, 1992 to 2005.
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Pollack et al S78.e6with worse survival for men and those who were
elderly at diagnosis. The difference in survival by age
may be related to comorbidities, which could not be
directly accounted using SEER data. Although we
observed survival differences by race and ethnicity
(for whites) in the unadjusted analysis, the associa-
tion of race and ethnicity with survival was attenu-
ated in the multivariate analysis.
Gender difference in melanoma survival have
been reported in other studies.9,14-16 Although this
observation is not well understood, previously
published findings have suggested that older pa-
tients are given the diagnosis at later stages as a result
of less screening; men are given the diagnosis of
more nodular melanoma, which has a poorer prog-
nosis; and that women undergo more screening and
have melanomas in more favorable anatomic loca-
tions.10,15,17,18 Our multivariate analysis results
showed that even adjusting for stage, the risk of
death from melanoma was still higher for men than
for women. Regarding race, the adjusted risk of
death for blacks was higher than for non-Hispanic
whites, but not statistically significant. This observa-
tion supports that there are racial differences in sex,
age, and clinical factors of melanoma at diagnosis,
which in turn impact survival. Previous studies have
shown that blacks are disproportionately affected by
acral lentiginous melanoma, a histologic subtype
with worse survival than overall melanoma, likely
because of acral lentiginous melanoma being diag-
nosed at later stages with thicker lesions.2,19 After
accounting for stage, depth, and histologic subtype,
we found survival differences for blacks compared
with whites were less than in previously published
work by Zell et al.5 Two major differences, however,
were that the analysis of Zell et al5 used onlyCalifornia Cancer Registry data with 127 cases of
melanoma among blacks, whereas our study used
national SEER-13 data that included over twice the
number of blacks; and, unlike the analysis of Zell
et al,5 we did not adjust for SES and treatment. SES
has been related to melanoma survival with in-
creased survival for nonwhites and elderly persons
with higher SES.4,5
We observed small improvements in survival at
the localized and regional stage. A factor that could
explain these observations and may have contrib-
uted to an increase in survival at these earlier stages is
the adoption of SLNB around the year 2000, a
technique that more precisely identifies potentially
affected lymph nodes.20 Using SLNB, some mela-
noma cases that may have been classified as local-
ized are identified as regional because of the
increased specificity of the diagnostic workup. As a
result of this upstaging, the survival at the regional
disease improves because of the addition of cases
that would have otherwise been classified as local-
ized, and survival at the localized stage also improves
because of the identification and classification of
more disseminated disease as regional stage.9,21 The
impact of SLNB on overall survival is a topic of much
debate in the current literature because the early
removal of lymph nodes with micrometastatic dis-
ease has not been shown to improve overall survival,
and there have been no randomized trials that have
shown that early surgical removal of affected nodes
improves overall survival compared with delaying
removal of nodes until they are clinically
palpable.22,23
We showed a small improvement in overall 5-year
survival from the early 1990s to the period around
the year 2000. During this time we found that more
cases were being staged; however, we did not
observe a dramatic shift toward melanoma being
diagnosed at earlier stages as might be expected
from increased screening for melanoma. In fact,
among the melanoma cases that were staged, from
the earliest to most recent time period, the percent-
age of all melanomas diagnosed at the localized
stage decreased and the percentage of all melano-
mas diagnosed at the regional stage increased. Jemal
et al24 showed that the incidence rates from 1992 to
2006 increased for all tumor depths, but did not take
into account nodal involvement, metastasis, or other
criteria that determine stage. Further exploration of
how the revised staging systems impact the relative
percentages of melanoma diagnosed at the localized
versus regional stage warrants further study.
Our cause-specific analysis focused on melanoma
as the underlying cause of death and did not include
death from all other causes. The validity of MSS
Fig 2. Unadjusted Kaplan-Meier melanoma-specific survival curves by stage (A), depth (B),
histology (C), and anatomic site (D), Surveillance, Epidemiology, and End Results-13, 1992 to
2005. NOS, Not otherwise specified.
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Understanding this, we believed that using MSS was
justified for our study because of the high quality of
SEER data, and because ascertaining death from
melanoma is not as challenging as other diseases as
a result of ease of obtaining diagnosis through
biopsy, and because of the tendency of disseminated
disease to metastasize and be detected. Another
approach we could have used is ‘‘relative survival,’’
which compares the observed survival of those given
the diagnosis of melanoma with a comparable pop-
ulation without melanoma, thus bypassing the need
for cause for death because of the focus on excess
mortality among those with melanoma.21 We chose
not to show relative survival because our preliminary
analyses using both cause-specific and relative sur-
vival were similar (data not shown) and because
there were no life tables available for racial and
ethnic groups besides black and white. ‘‘Period
survival’’ is an approach that captures improvementsin survival to provide better estimates of long-term
survival for more recently diagnosed cancer.25 Given
the lack of significant progress in survival shown in
our study (Table II), using period survival was
unnecessary. A more recent, relevant approach is
‘‘conditional survival,’’ which conditions survival
upon living to a certain time point, and has been
applied to melanoma by Rueth et al26 to show that 8
years after surgical treatment from melanoma, the
survival for high-risk melanoma is similar to low-risk
disease.
Strengths of this study were the use of population-
based, high-quality SEER data and the large number
of melanoma cases, including cases among those
who were black or Hispanic. A limitation is that we
were unable to use the complete US Cancer Statistics
data set (SEER combined with National Program of
Cancer Registries data)1 because the survival data are
not consistently available from all National Program
of Cancer Registries. Other limitations include the
Table II. Overall melanoma-specific 5-year survival by specified time periods, Surveillance, Epidemiology, and
End Results-13, 1992 to 2005
Period I Period II Period III
1992-1995 1996-1998 1999-2001
N (%) 5-y Survival, % (95% CI) N (%) 5-y Survival, % (95% CI) N (%) 5-y Survival, % (95% CI)
Overall 16,262 87.7 (87.1-88.2) 14,286 89.1 (88.5-89.6) 15,604 90.1 (89.6-90.5)
Staged 15,304 (94.1) 88.1 (87.5-88.6) 13,647 (95.5) 88.1 (87.5-88.6) 15,272 (97.9) 90.3 (89.8-90.7)
Unstaged 958 (5.9) 80.9 (78.2-83.3) 639 (4.5) 80.0 (76.6-83.0) 332 (2.1) 79.6 (74.6-83.7)
Staged
Localized 13,223 (86.4) 94.3 (93.8-94.6) 11,726 (85.9) 95.6 (95.2-96.0) 12,922 (84.6) 96.4 (96.1-96.7)
Regional 1518 (9.9) 59.4 (56.8-62.0) 1468 (10.8) 61.3 (56.8-63.8) 1869 (12.2) 65.5 (63.2-67.7)
Distant 563 (3.7) 14.0 (11.1-17.2) 453 (3.3) 16.4 (13.0-20.2) 481 (3.2) 16.6 (13.0-20.2)
Cases diagnosed after 2001 were excluded to have a full 5 years of follow-up. Percentages may not add to 100 because of rounding.
CI, Confidence interval.
Table III. Cox multivariate analysis of 5-year
survival for malignant melanoma, Surveillance,
Epidemiology, and End Results-13, 1992 to 2005

























No tumor found 3.03 (1.98-4.64)
CI, Confidence interval.
*Survival estimates are from Cox proportional hazards model
accounting for histologic subtype, anatomic site, sex, age at
diagnosis, race/ethnicity, stage at diagnosis, and depth.
ySurveillance, Epidemiology, and End Results (SEER) historic stage
based on SEER summary stage 2000.
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Cancer Registries Hispanic Identification Algorithm,
which may misclassify Hispanic ethnicity because of
the reliance of surname and other demographic
variables rather than self-report.11 We did notaccount for all factors known to impact survival
including treatment, prognostic factors in the revised
staging system (nodal involvement, metastasis, and,
more recently, mitoses, ulceration, and serum lactate
dehydrogenase), SES, and physician specialty or
availability as these data are not available in
population-based registries.4,5,14,27,28 Also, we ex-
amined survival after diagnosis of the ‘‘first and
primary’’ melanoma but did not limit cases to ‘‘first
and only’’ melanoma. Thus, our data include people
who may have had subsequent cancers, melanoma
or otherwise, after a primary diagnosis of melanoma.
It is important to be aware that certain medical
conditions, such as atypical mole (dysplastic nevi)
syndrome or immunosuppression, may predispose
one to multiple diagnoses of melanoma and may
impact survival.29-35
The contrast in melanoma survival by stage at
diagnosis offers a compelling reason to support early
detection and to support primary prevention
through sun protection and avoidance of harmful
ultraviolet light; these prevention efforts should be
emphasized. Although, routine screening for early
detection of lesions is not currently recommended
by the US Preventive Services Task Force and Cancer
Council Australia,36-38 early detection through
screening should be considered for persons at risk
for melanoma. Previous studies have found such
screening program to be cost-effective, even if
screening is not currently recommended. For in-
stance, Freedberg et al39 used data from the US
population and estimated a cost-effectiveness ratio
of $29,170 per year of life saved for a one-time
screening of self-selected patients at high-risk with a
mean age of 48 years. Further, a study from Australia
estimated a cost-effectiveness of annual melanoma
screening in Australians aged 50 years or older to be
Aust. $12,137 and Aust. $20,877 (US$12,318 and
US$21,188) for men and women, respectively.40
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S78.e9 Pollack et alIn conclusion, our study found minimal progress
in survival from 1992 to 2005. The relevance of new
therapies such as interferon alfa-2b and, more re-
cently, immunotherapy (eg, ipilimumab) on prog-
nosis will be determined in future studies.20,41 Until
then, efforts to reduce melanoma deaths must con-
tinue through prevention, screening of persons at
high risk, and elimination of disparities that lead to
late diagnosis.
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